(3R)-3-(乙酰氨基)-1-吡咯烷羧酸叔丁酯 | 550371-67-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (3R)-3-(乙酰氨基)-1-吡咯烷羧酸叔丁酯
• 中文别名: (R)-(+)-1-Boc-3-乙酰氨基吡咯烷
• 英文名称: (R)-(+)-1-Boc-3-acetamidopyrrolidine
• 英文别名: tert-butyl (3R)-3-acetamidopyrrolidine-1-carboxylate
• CAS: 550371-67-0
• 化学式: C₁₁H₂₀N₂O₃
• 分子量: 228.29
• InChiKey: SLFZPSKIMUPQSR-SECBINFHSA-N

物化性质

• 熔点：
  85-89 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 海关编码：
  2933990090
• WGK Germany：
  2

文献信息

• HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20200172508A1

  公开（公告）日：2020-06-04

  The present invention encompasses compounds of the formula I which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

  本发明涵盖了适用于治疗与Vanin相关疾病的化合物I的公式，以及制备这些化合物的方法、含有这些化合物的药物制剂，以及它们的使用方法。
• NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM
  申请人：Pelletier Jeffrey Claude

  公开号：US20090054392A1

  公开（公告）日：2009-02-26

  The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analog.

  本发明涉及萘基嘧啶类似物、制备萘基嘧啶类似物的方法、包含萘基嘧啶类似物的组合物以及治疗与经典Wnt-β-catenin细胞信息传递系统相关的疾病的方法，包括向需要治疗的受试者投予有效量的萘基嘧啶、萘基吡嗪和萘基吡啶类似物。
• 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS
  申请人：Mission Therapeutics Limited

  公开号：EP3943490A1

  公开（公告）日：2022-01-26

  The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, R12, Z, Y and m are as defined herein.

  本发明涉及新型化合物和去泛素化酶（DUB）抑制剂的制造方法。特别是，本发明涉及泛素 C 端水解酶 30（USP30）的抑制。本发明还涉及 DUB 抑制剂在治疗线粒体功能障碍和癌症方面的用途。本发明的化合物包括具有式(II)的化合物 或其药学上可接受的盐，其中 R1、R2、R3、R4、R5、R8、R9、R10、R12、Z、Y 和 m 如本文所定义。
• Heteroaromatic compounds as Vanin inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：US11078182B2

  公开（公告）日：2021-08-03

  The present invention encompasses compounds of the formula I which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

  本发明包括式 I 的化合物 适用于治疗与 Vanin 有关的疾病的式 I 化合物，以及制造这些化合物的工艺、含有这些化合物的药物制剂及其使用方法。
• Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV)
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：US11339165B2

  公开（公告）日：2022-05-24

  The invention concerns compounds having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. Formula (Ia).

  本发明涉及具有抗病毒活性的化合物，尤其是对呼吸道合胞病毒（RSV）的复制具有抑制活性的化合物。本发明还涉及包含这些化合物的药物组合物以及用于治疗呼吸道合胞病毒感染的化合物。式 (Ia).